Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 1 Rhabdomyosarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Neurofibromatosis 2 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 2a 1 Mesothelioma, Malignant 1 Medulloblastoma 1 Lethal Congenital Contracture Syndrome 2 1 Hemangiosarcoma 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 113 Cisplatin 77 Oxaliplatin 46 pembrolizumab 35 Fluorouracil 33 Capecitabine 31 durvalumab 27 Leucovorin 27 lenvatinib 26 Magnetic Resonance Spectroscopy 15 Irinotecan 14 Drug Therapy 13 Biopsy 13 Nivolumab 12 Albumin-Bound Paclitaxel 12 tislelizumab 11 Specimen Handling 11 Radiofrequency Ablation 11 130-nm albumin-bound paclitaxel 11 pemigatinib 10 apatinib 10 Taxes 10 Radiotherapy 10 Floxuridine 10 Folfox protocol 9 Bevacizumab 9 S 1 (combination) 8 Platinum 8 Photochemotherapy 8 Liver Transplantation 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cholangiocarcinoma × Vascular Endothelial Growth Factor A × Clear all

NCT02893085 2016-12-28

ONCOBIL

CHU de Reims

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡